Compare Amgen, Inc. (AMGN) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Advanced Drainage Systems Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Advanced Drainage Systems Inc trades at $147.16 (market cap $11.53B). The key difference: Amgen, Inc. is far larger — about 17× Advanced Drainage Systems Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WMS | |
|---|---|---|
Market Cap | $196.12B | $11.53B |
Sector | Health | Industrials |
52-Week High | $388.16 | $175.38 |
52-Week Low | $271.18 | $110.89 |
Enterprise Value | $241.41B | $13.10B |
Dividend Yield | 2.77% | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Advanced Drainage Systems (WMS) trades at $150.47, up 1.77% today, with a bullish technical signal and strong fundamental profitability. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.07 exceeding the $0.936 estimate. The company maintains robust margins, including a 38.27% gross profit margin and 13.98% net income margin, while cash flow trends indicate solid operational performance despite a net outflow in 2025.
The outlook is positive with a consensus price target of $183.33, suggesting 22% upside, supported by analyst buy ratings. Risks include competitive pressures and a recent Zacks Strong Sell rating, but strong ROE of 24.02% and debt-to-asset improvement to 34.34% in 2025 highlight financial health. Investors should weigh growth potential against market volatility and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
